Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins, AmpTec to Co-market Synthetic RNAs

NEW YORK (GenomeWeb) — Eurofins Genomics and AmpTec have agreed to non-exclusively co-market AmptTec's IVT-RNAs globally under a deal announced today.

The co-marketing agreement covers in vitro transcribed single-stranded, double-stranded, and functional synthetic mRNAs that can be used in a variety of applications including in vitro diagnostics of pathogens, rare mutation detection, and companion diagnostics, Eurofins said.

Together the companies will offer custom services for synthetic genes and very long synthetic RNAs to an international market, Eurofins added.

"The cooperation will allow us to broaden Eurofins' portfolio with innovative nucleic acid products," Bruno Poddevin, senior vice president of Eurofins Genomics, said in a statement. "By sharing best practices, clients will benefit from an unparalleled spectrum of custom services for IVT-RNAs, which in turn should fuel further market share growth for both partners."

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.